Employees: 637
Size MedCap (MCAP.ST) is a Sweden Health Care company (Medical Specialties) with a market value of $811M, the 143rd largest of 220 Sweden companies the cockpit tracks. Shares closed at SEK 547.00 on 18 Nov 2026.
Performance Over six months the shares fell 4.1%, against -15.2% for the median peer and +2.8% for the Sweden market (cap-weighted) — 9th highest of 21 in its peer set.
Growth Revenue grew 16.5% over the last twelve months (peer median +6.2%); the operating margin is 14.7% (peer median 9.4%).
Valuation It trades at 25.8× forward earnings against a peer median of 19.9× (3rd most expensive of 13).
Price implies For today's price to make sense, revenue must grow about 3% a year for seven years (Req g). Recent delivered growth is +21%, so the hurdle is -18 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 9.2 points above its cost of capital (5.3% WACC).
Next results Next results expected around 5 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | SEK 2.32B | SEK 2.11B | SEK 1.81B | SEK 1.59B | SEK 1.11B |
| Revenue growth | — | +17% | +14% | +43% | — |
| Gross profit | SEK 341M | SEK 321M | SEK 258M | SEK 236M | SEK 165M |
| EBITDA | SEK 528M | SEK 433M | SEK 346M | SEK 311M | SEK 221M |
| Net income | SEK 274M | SEK 220M | SEK 207M | SEK 172M | SEK 118M |
| Free cash flow | SEK 397M | SEK 317M | SEK 318M | SEK 206M | SEK 59.2M |
| Capital expenditure | SEK 68.9M | SEK 62.2M | SEK 66.2M | SEK 39.3M | SEK 44.3M |
| Total debt | SEK 438M | SEK 483M | SEK 358M | SEK 261M | SEK 340M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | MCAP.ST | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +1.4% | -5.1% | 6th highest of 21 |
| 6-month return | -4.1% | -15.2% | 9th highest of 21 |
| Distance from 52-week high | -9.5% | -39.8% | 6th highest of 21 |
| Revenue growth (TTM) | +16.5% | +6.2% | 6th highest of 21 |
| Operating margin | 14.7% | 9.4% | 5th highest of 21 |
| Forward P/E | 25.8× | 19.9× | 3rd most expensive of 13 |
| Growth the price implies (Req g, 7 yrs) | 2.7% | 9.6% | 5th least demanding of 14 |
| Growth delivered (Del g) | +20.9% | +11.3% | 3rd highest of 14 |
| Hurdle (Req g minus delivered) | -18.2 pp | +6.5 pp | 3rd least demanding of 14 |
| ROIC minus cost of capital | +9.2 pp | -1.9 pp | 3rd highest of 21 |
| EV / EBITDA | 15.9× | 13.1× | 4th most expensive of 9 |
| Net debt / EBITDA | 0.3× | 0.1× | 5th most indebted of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| MedCap MCAP.ST | Sweden | $811M | -4% | +17% | 15% | 25.8× | 2.7% | +20.9% |
| Advanced Medical Solutions AMS.L | United Kingdom | $811M | +27% | +6% | 12% | 20.7× | 20.0% | +21.4% |
| Seegene 096530.KS | South Korea | $808M | -26% | +13% | 13% | 20.0× | -6.7% | -15.9% |
| Beijing Hotgen Biotech 688068.SS | China | $815M | -37% | +8% | -94% | n/a | n/a | n/a |
| Ningbo Jansen Superconducting Technologies 688805.SS | China | $818M | -36% | +36% | 16% | n/a | 35.6% | +17.1% |
| OrthoPediatrics KIDS | United States | $826M | +71% | +16% | -8% | n/a | n/a | n/a |
| Cofoe Medical Technology 1187.HK | Hong Kong | $836M | -11% | +40% | 10% | 13.1× | -6.4% | +6.6% |
| Standard Engineering Technology SETL.NS | India | $783M | +168% | +45% | 14% | n/a | n/a | n/a |
| Cisen Pharmaceutical 603367.SS | China | $843M | -15% | -6% | 8% | 7.9× | -14.6% | -1.3% |
| Modern Dental 3600.HK | Hong Kong | $844M | +24% | +12% | 22% | 8.5× | -7.1% | +11.3% |
| Beta Bionics BBNX | United States | $779M | +42% | +44% | -73% | n/a | n/a | n/a |
| Mesa Laboratories MLAB | United States | $775M | +33% | +2% | 10% | 11.5× | 21.3% | +13.2% |
| Cytek Biosciences CTKB | United States | $774M | +57% | +6% | -21% | n/a | n/a | n/a |
| LifeTech Scientific 1302.HK | Hong Kong | $771M | -30% | +1% | 12% | 19.8× | 9.6% | +15.5% |
| Varex Imaging VREX | United States | $771M | +79% | +5% | 8% | 19.9× | n/a | n/a |
| Zylox-Tonbridge Medical Technology 2190.HK | Hong Kong | $768M | -16% | +39% | 25% | 14.4× | 3.8% | +105.8% |
| Shantou Institute of Ultrasonic Instruments 301602.SZ | China | $858M | -25% | +4% | 30% | n/a | 11.1% | +4.6% |
| HOB Biotech 688656.SS | China | $858M | -33% | +6% | 7% | 166.9× | 37.6% | +12.4% |
| Beijing SDL Technology 002658.SZ | China | $864M | -34% | -13% | 9% | 22.4× | 16.8% | +2.9% |
| Maccura Biotechnology 300463.SZ | China | $756M | -18% | -1% | -4% | 421.0× | 7.9% | -10.2% |
| Tinavi Medical Technologies 688277.SS | China | $872M | -36% | -2% | -59% | n/a | n/a | n/a |